+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Muscle Relaxants Drug Market - Global Forecast 2026-2032- Product Image
Muscle Relaxants Drug Market - Global Forecast 2026-2032- Product Image
Sale

Muscle Relaxants Drug Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968778
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Muscle Relaxants Drug Market is projected to reach USD 5.10 Billion in 2026. It is expected to continue growing at a CAGR of 4.27%, reaching USD 6.57 Billion by 2032.

The muscle relaxants drug market is anchored by two durable clinical needs: short-term relief of acute musculoskeletal spasm and long-term management of spasticity associated with neurologic disorders such as multiple sclerosis, cerebral palsy, stroke, and spinal cord injury. Demand is supported by the global burden of back pain and mobility-limiting conditions; the World Health Organization identifies low back pain as the leading cause of disability worldwide, affecting hundreds of millions of people and creating sustained need for evidence-based pain and rehabilitation pathways.

Commercial growth is shaped by a mature generic base, increasing scrutiny of sedating medicines, and ongoing differentiation through improved formulations, intrathecal delivery, targeted neuromodulation, and combination care models. Industry leaders competing in muscle relaxant drugs must balance affordability, clinical utility, safety monitoring, and payer expectations while positioning products within broader pain management, orthopedic, neurology, and rehabilitation ecosystems.

Transformative Shifts in the Muscle Relaxants Landscape

The landscape is shifting from broad symptomatic prescribing toward more selective, guideline-aligned use. Clinicians are increasingly differentiating centrally acting skeletal muscle relaxants used for acute back or neck pain from antispasticity agents such as baclofen, tizanidine, dantrolene, and benzodiazepines used in neurologic spasticity. This shift reflects stronger attention to duration of therapy, functional outcomes, fall risk, sedation, hepatic monitoring, and drug-drug interactions.

Another transformative force is the movement away from opioid-centered pain pathways. Health systems are expanding multimodal treatment models that combine non-opioid pharmacotherapy, physical therapy, behavioral health, interventional procedures, and digital rehabilitation. At the same time, geriatric prescribing standards such as the American Geriatrics Society Beers Criteria caution against many skeletal muscle relaxants in older adults because of anticholinergic effects, sedation, and fracture risk, creating both market constraints and opportunities for safer, better-targeted therapies.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the muscle relaxants drug market across discovery, development, pharmacovigilance, and commercialization. In research, AI-enabled modeling can help identify receptor activity, optimize chemical libraries, and predict off-target toxicity earlier in development. For established drugs, machine learning can analyze real-world evidence to identify patient groups at higher risk of excessive sedation, falls, misuse, hepatic injury, or treatment discontinuation.

The cumulative impact is strongest where AI connects prescribing behavior with outcomes. Clinical decision support can flag duplicate central nervous system depressants, benzodiazepine co-use, alcohol-related risk, renal or hepatic impairment considerations, and geriatric contraindications. For manufacturers, AI-driven medical affairs and market access analytics can support evidence generation, adherence programs, label strategy, and post-market safety surveillance while remaining aligned with FDA, EMA, and local data governance expectations.

Key Regional Insights

Asia-Pacific is becoming a high-priority region as aging populations, road traffic injuries, occupational strain, and expanding access to specialty care increase demand for musculoskeletal and neurologic treatment. China, India, Japan, South Korea, and Australia each show distinct opportunity patterns, ranging from high-volume generic use and domestic manufacturing strength to advanced rehabilitation and specialty neurology care. Local pricing controls, hospital formularies, essential medicine policies, and regulatory requirements remain decisive competitive factors.

North America remains one of the most closely monitored markets due to payer oversight, opioid stewardship, electronic prescribing systems, and mature pharmacovigilance infrastructure. Europe benefits from structured reimbursement, strong clinical guideline adoption, and active health technology assessment practices, while Latin America shows demand linked to primary care, trauma, occupational injury, and rising private healthcare access. The Middle East is supported by hospital infrastructure investment, particularly in Gulf economies, whereas Africa remains shaped by affordability, essential medicine access, supply reliability, and uneven specialist availability.

Key Group Insights

ASEAN markets are characterized by expanding healthcare access, urbanization, and strong demand for affordable generics, with hospital procurement, retail pharmacy networks, and national reimbursement policies influencing uptake. The GCC is more hospital-centric, supported by government-funded healthcare modernization, medical tourism ambitions, and specialist neurology and orthopedic services. These markets often favor suppliers that can demonstrate quality, regulatory reliability, pharmacovigilance readiness, and supply continuity.

The European Union emphasizes pharmacovigilance, cost-effectiveness, and harmonized regulatory expectations, making evidence quality critical for market access. BRICS economies combine large patient populations with price sensitivity, rising domestic production capacity, and high need for musculoskeletal and neurologic care. G7 markets are defined by advanced prescribing controls, aging demographics, and high safety expectations, while NATO countries broadly reflect stronger emergency care, rehabilitation systems, and defense-related trauma care needs that can influence institutional demand for pain and spasticity management therapies.

Key Country Insights

The United States leads in commercial complexity, with strong demand for non-opioid pain options but strict payer management, opioid-sparing care pathways, and safety-focused prescribing. Canada shows similar caution with emphasis on public reimbursement, formulary review, and appropriate use. Mexico and Brazil are influenced by mixed public-private access, high generic utilization, and growing treatment needs for work-related injury, trauma-associated musculoskeletal conditions, and neurologic rehabilitation.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on guideline-driven care, cost controls, and established rehabilitation pathways, while Russia maintains demand across neurologic and musculoskeletal indications with local registration, reimbursement, and supply considerations. China and India offer scale, manufacturing depth, and large treatment populations; Japan and South Korea emphasize aging-related care quality, safety, and specialist-led treatment; and Australia combines strong regulatory oversight with evidence-based primary care and rehabilitation integration.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated evidence rather than relying only on legacy prescribing. Comparative effectiveness studies, real-world safety analyses, and functional outcome data can strengthen payer confidence and support responsible use. Companies should also invest in formulations or delivery systems that reduce peak sedation, improve adherence, or support targeted spasticity management.

Commercial teams should align messaging with opioid-sparing pain care, geriatric risk reduction, rehabilitation integration, and neurologic spasticity management. Market access strategies must account for regional pricing pressure, generic competition, pharmacovigilance obligations, and country-specific prescribing controls. Partnerships with rehabilitation providers, digital health platforms, and health systems can improve patient outcomes while creating defensible positioning in the muscle relaxants drug market.

Research Methodology

This executive summary is based on a structured research approach that triangulates regulatory guidance, clinical practice standards, epidemiology, prescribing trends, product availability, patent and generic status, reimbursement signals, and healthcare infrastructure indicators. Sources typically reviewed include public information from agencies such as the FDA, EMA, WHO, national health authorities, peer-reviewed journals, clinical guideline bodies, and recognized pharmacovigilance resources.

The methodology emphasizes validated, cross-checked insights over speculative forecasting. Market interpretation considers disease burden, treatment algorithms, safety warnings, competitive intensity, supply chain reliability, physician adoption, payer behavior, and regional access conditions. Findings are synthesized to support strategic planning for manufacturers, distributors, investors, and healthcare stakeholders in the muscle relaxants drug market.

Conclusion

The muscle relaxants drug market remains clinically relevant, but future growth depends on safer prescribing, stronger evidence, and sharper segmentation between acute musculoskeletal spasm and chronic neurologic spasticity. Mature generics will continue to dominate utilization, while innovation opportunities will cluster around improved tolerability, targeted delivery, real-world evidence, and integrated rehabilitation models.

Organizations that combine regulatory discipline, AI-enabled safety intelligence, regional market access expertise, and patient-centered outcomes will be better positioned to compete. As healthcare systems demand measurable value and reduced medication-related harm, the most successful strategies will align muscle relaxant therapy with functional recovery, responsible pain management, and long-term quality of life.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Muscle Relaxants Drug Market, by Product Type
7.1. Introduction
7.2. Neuromuscular Blocker
7.2.1. Depolarizing
7.2.2. Non Depolarizing
7.3. Spasmolytic
7.3.1. Centrally Acting
7.3.2. Direct Acting
8. Muscle Relaxants Drug Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
9. Muscle Relaxants Drug Market, by Drug Form
9.1. Introduction
9.2. Capsule
9.3. Injectable Solution
9.4. Liquid
9.5. Tablet
10. Muscle Relaxants Drug Market, by Clinical Indication
10.1. Introduction
10.2. Acute Musculoskeletal Conditions
10.3. Neurological Spasticity
10.4. Surgical Procedures
10.5. Critical Care Ventilation
11. Muscle Relaxants Drug Market, by Patient Age Group
11.1. Introduction
11.2. Pediatric
11.3. Adult
11.4. Geriatric
12. Muscle Relaxants Drug Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Muscle Relaxants Drug Market, by Distribution Channel
13.1. Introduction
13.2. Online
13.2.1. Manufacturer Websites
13.2.2. Third Party E Retailers
13.3. Offline
14. Muscle Relaxants Drug Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Muscle Relaxants Drug Market, by Group
15.1. NATO
15.2. G7
15.3. BRICS
15.4. European Union
15.5. ASEAN
15.6. GCC
16. Muscle Relaxants Drug Market, by Country
16.1. China
16.2. United States
16.3. Japan
16.4. India
16.5. Germany
16.6. United Kingdom
16.7. Australia
16.8. France
16.9. South Korea
16.10. Italy
16.11. Canada
16.12. Russia
16.13. Brazil
16.14. Mexico
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Acorda Therapeutics, Inc.
18.2. Amneal Pharmaceuticals LLC
18.3. Aurobindo Pharma Limited
18.4. Bausch Health Companies Inc.
18.5. Cipla Limited
18.6. Dr. Reddy's Laboratories Limited
18.7. Endo International plc
18.8. Fresenius Kabi AG
18.9. Hikma Pharmaceuticals PLC
18.10. Lupin Limited
18.11. Novartis AG
18.12. Pfizer Inc.
18.13. Sandoz International GmbH
18.14. Stada Arzneimittel AG
18.15. Sun Pharmaceutical Industries Limited
18.16. Torrent Pharmaceuticals Limited
18.17. Upsher-Smith Laboratories, LLC
18.18. Viatris Inc.
18.19. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL MUSCLE RELAXANTS DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MUSCLE RELAXANTS DRUG MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MUSCLE RELAXANTS DRUG MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MUSCLE RELAXANTS DRUG MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL MUSCLE RELAXANTS DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL MUSCLE RELAXANTS DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL MUSCLE RELAXANTS DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NEUROMUSCULAR BLOCKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NEUROMUSCULAR BLOCKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NEUROMUSCULAR BLOCKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DEPOLARIZING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DEPOLARIZING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DEPOLARIZING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL NON DEPOLARIZING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL NON DEPOLARIZING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL NON DEPOLARIZING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SPASMOLYTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SPASMOLYTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SPASMOLYTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CENTRALLY ACTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CENTRALLY ACTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CENTRALLY ACTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL DIRECT ACTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL DIRECT ACTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL DIRECT ACTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LIQUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ACUTE MUSCULOSKELETAL CONDITIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ACUTE MUSCULOSKELETAL CONDITIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ACUTE MUSCULOSKELETAL CONDITIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL NEUROLOGICAL SPASTICITY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NEUROLOGICAL SPASTICITY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NEUROLOGICAL SPASTICITY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SURGICAL PROCEDURES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SURGICAL PROCEDURES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SURGICAL PROCEDURES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CRITICAL CARE VENTILATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CRITICAL CARE VENTILATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CRITICAL CARE VENTILATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL MANUFACTURER WEBSITES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL MANUFACTURER WEBSITES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL MANUFACTURER WEBSITES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL THIRD PARTY E RETAILERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL THIRD PARTY E RETAILERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL THIRD PARTY E RETAILERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 100. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 102. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 103. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 104. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 105. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 106. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 107. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 108. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 110. EUROPE MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 133. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 135. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 136. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 137. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 138. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 139. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 140. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 141. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 143. AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 158. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 159. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 160. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 161. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 162. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 163. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 164. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 165. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 166. NATO MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 167. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 169. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 170. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 171. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 172. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 173. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 174. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 175. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 177. G7 MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 178. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 180. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 181. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 182. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 183. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 184. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 185. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 186. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 188. BRICS MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 200. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 201. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 202. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 203. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 204. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 205. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 206. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 207. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 208. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 210. ASEAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 211. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 212. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 213. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 214. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 215. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 216. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 217. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 218. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 219. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. GCC MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 222. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 223. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 225. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 226. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 227. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 229. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 230. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 231. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 233. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 245. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 247. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 248. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 249. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 250. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 251. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 252. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 253. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 255. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 256. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 258. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 259. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 260. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 261. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 262. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 263. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 264. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 265. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 266. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 267. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 268. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 269. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 270. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 271. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 272. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 273. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 274. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 275. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 289. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 293. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 294. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 295. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 296. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 297. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 299. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 300. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 302. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 303. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 304. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 305. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 306. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 307. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 308. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 310. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 311. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 313. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 314. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 315. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 316. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 317. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 318. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 319. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 320. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 321. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 322. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 323. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 324. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 325. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 326. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 327. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 328. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 329. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 330. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 331. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 332. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 333. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 334. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 335. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 336. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 337. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 338. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 339. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 340. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 341. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 342. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 343. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE, 2017-2032 (USD MILLION)
TABLE 344. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 345. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 346. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR BLOCKER, 2017-2032 (USD MILLION)
TABLE 347. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY SPASMOLYTIC, 2017-2032 (USD MILLION)
TABLE 348. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 349. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG FORM, 2017-2032 (USD MILLION)
TABLE 350. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 351. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 352. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABL

Companies Mentioned

  • Acorda Therapeutics, Inc.
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Endo International plc
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Stada Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals Limited
  • Upsher-Smith Laboratories, LLC
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.1 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.57 Billion
Compound Annual Growth Rate4.2%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Muscle Relaxant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Muscle Relaxant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 114 Pages
  • Global
From
Muscle Relaxant Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Muscle Relaxant Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 182 Pages
  • Global
From
Muscle Relaxant Drug Market Report: Trends, Forecast and Competitive Analysis to 2035 - Product Image

Muscle Relaxant Drug Market Report: Trends, Forecast and Competitive Analysis to 2035

  • Report
  • 177 Pages
  • Global
From
Muscle Relaxant Drugs Market Report 2026 - Product Image

Muscle Relaxant Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Muscle Relaxant Drugs - Global Strategic Business Report - Product Image

Muscle Relaxant Drugs - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From

About the Muscle Relaxant Market

The Muscle Relaxant market is a subset of the Central Nervous System Drugs market. Muscle relaxants are drugs that are used to reduce muscle spasms, tension, and stiffness. They are commonly used to treat conditions such as muscle spasms, neck and back pain, fibromyalgia, and multiple sclerosis. Muscle relaxants can be divided into two categories: non-depolarizing and depolarizing. Non-depolarizing muscle relaxants are used to reduce muscle spasms and tension, while depolarizing muscle relaxants are used to reduce muscle stiffness. The Muscle Relaxant market is highly competitive, with a number of companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Novartis, GlaxoSmithKline, and Sanofi. These companies offer a range of products, including non-depolarizing and depolarizing muscle relaxants, as well as combination products. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.